Clinical TrialMay 26, 2026, 05:12 PM
Lipocine Presents Phase 3 Clinical Data for LPCN 1154 PPD Treatment
AI Summary
Lipocine Inc. presented its Phase 3 clinical data for LPCN 1154 at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting held from May 26-29, 2026. The presentation highlighted the results from the company's placebo-controlled trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD). This marks a significant update in the development of the potential PPD treatment.
Key Highlights
- Lipocine presented Phase 3 clinical data for LPCN 1154.
- The data was presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting.
- LPCN 1154 is an oral brexanolone for the treatment of postpartum depression (PPD).
- The presentation highlighted results from a placebo-controlled Phase 3 trial.
Price Impact
More from LPCN